Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment (INTEREST)

12 novembre 2026 aggiornato da: University Hospital, Brest

Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.

Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.

This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Descrizione dettagliata

Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.

Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.

The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.

The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.

The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
  • Stable cytoreductive therapy for at least 6 months
  • Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
  • Adult patient capable of providing informed consent

Exclusion Criteria:

  • Recurrent or poorly controlled infections
  • Thrombocytopenia < 100 G/L
  • Neutropenia < 1 G/L
  • Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
  • Concomitant immunosuppressive therapy
  • Refusal to participate
  • Patient under legal protection (guardianship, curatorship, etc.)
  • Patients unable to consent.
  • Positive urine pregnancy test at screening / pregnant or breastfeeding women.
  • Lack of understanding of questionnaires or inability to follow up.
  • Women of childbearing potential unwilling to use a highly effective contraceptive methods

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Anakinra + cytoreductive therapy

Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence.

Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary.

Nessun intervento: Cytoreductive therapy alone

Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in serum calprotectin levels
Lasso di tempo: Baseline and Month 3

Calprotectin levels are measured on serum samples by centralized analysis (µg/mL)

Baseline and Month 3

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Improvement (yes/no) of the response status between baseline and month 3.
Lasso di tempo: Month 3

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 3
Improvement (yes/no) of the response status between baseline and month 6.
Lasso di tempo: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Improvement (yes/no) of the response status between month 3 and month 6.
Lasso di tempo: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Hemoglobin count
Lasso di tempo: Baseline

Measurement of Hemoglobin in g/dL

Baseline
Hematocrit count
Lasso di tempo: Baseline

Measurement of Hematocrit in %

Baseline
White blood cell count
Lasso di tempo: Baseline

Measurement of WBC in G/L

Baseline
Platelet cell count
Lasso di tempo: Baseline

Measurement of Platelets in G/L

Baseline
Hemoglobin count
Lasso di tempo: Month 3

Measurement of Hemoglobin in g/dL

Month 3
Hematocrit count
Lasso di tempo: Month 3

Measurement of Hematocrit in %

Month 3
White blood cell count
Lasso di tempo: Month 3

Measurement of WBC in G/L

Month 3
Platelet cell count
Lasso di tempo: Month 3

Measurement of Platelets in G/L

Month 3
Hemoglobin count
Lasso di tempo: Month 6

Measurement of Hemoglobin in g/dL

Month 6
Hematocrit count
Lasso di tempo: Month 6

Measurement of Hematocrit in %

Month 6
White blood cell count
Lasso di tempo: Month 6

Measurement of WBC in G/L

Month 6
Platelet cell count
Lasso di tempo: Month 6

Measurement of Platelets in G/L

Month 6
Treatment-related adverse event for experimental group
Lasso di tempo: Month 1

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 1
Treatment-related adverse event for experimental group
Lasso di tempo: Month 3

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 3
Treatment-related adverse event for experimental group
Lasso di tempo: Month 6

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 6
Adherence to treatment regimen for experimental group
Lasso di tempo: Month 1

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation.

Month 1
Adherence to treatment regimen for experimental group
Lasso di tempo: Month 2

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation

Month 2
Adherence to treatment regimen for experimental group
Lasso di tempo: Month 3

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation.

Month 3
QLQ-C30 Summary Score
Lasso di tempo: Baseline

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Baseline
QLQ-C30 Summary Score
Lasso di tempo: Month 3

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 3
QLQ-C30 Summary Score
Lasso di tempo: Month 6

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 6
Global health status / QoL score
Lasso di tempo: Baseline

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Baseline
Global health status / QoL score
Lasso di tempo: Month 3

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 3
Global health status / QoL score
Lasso di tempo: Month 6

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 6
Patient-reported symptom severity over the previous 4 weeks for pruritus
Lasso di tempo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever
Lasso di tempo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Lasso di tempo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for pruritus
Lasso di tempo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever
Lasso di tempo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Lasso di tempo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for pruritus
Lasso di tempo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever
Lasso di tempo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Lasso di tempo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Inflammatory biological profile
Lasso di tempo: Baseline

Measurement of IL-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Lasso di tempo: Month 3

Measurement of IL-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Lasso di tempo: Month 6

Measurement of IL-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Lasso di tempo: Baseline

Measurement of IL-6 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Lasso di tempo: Month 3

Measurement of IL-6 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Lasso di tempo: Month 6

Measurement of IL-6 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Lasso di tempo: Baseline

Measurement of IL-8 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Lasso di tempo: Month 3

Measurement of IL-8 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Lasso di tempo: Month 6

Measurement of IL-8 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Lasso di tempo: Baseline

Measurement of MIP-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Lasso di tempo: Month 3

Measurement of MIP-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Lasso di tempo: Month 6

Measurement of MIP-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Lasso di tempo: Baseline

Measurement of TNF-α cytokines in pg/mL.

Baseline
Inflammatory biological profile
Lasso di tempo: Month 3

Measurement of TNF-α cytokines in pg/mL.

Month 3
Inflammatory biological profile
Lasso di tempo: Month 6

Measurement of TNF-α cytokines in pg/mL.

Month 6
Allele burden of the driver mutation
Lasso di tempo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Baseline
Allele burden of the driver mutation
Lasso di tempo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 3
Allele burden of the driver mutation
Lasso di tempo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 6
Allele burden of the driver mutation
Lasso di tempo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Baseline
Allele burden of the driver mutation
Lasso di tempo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 3
Allele burden of the driver mutation
Lasso di tempo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 6
Allele burden of the driver mutation
Lasso di tempo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Baseline
Allele burden of the driver mutation
Lasso di tempo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 3
Allele burden of the driver mutation
Lasso di tempo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 6
Fibrosis markers
Lasso di tempo: Baseline

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Baseline
Fibrosis markers
Lasso di tempo: Month 3

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 3
Fibrosis markers
Lasso di tempo: Month 6

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 6

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 febbraio 2027

Completamento primario (Stimato)

1 agosto 2028

Completamento dello studio (Stimato)

1 agosto 2028

Date di iscrizione allo studio

Primo inviato

3 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi